Britain’s departure from the European Union (EU) will necessitate a vast amount of changes, including a new location for the European Medicines Agency (EMA). Its leader worries that the move could slow down the drug approval pipeline.
Last week, Britain formally announced its intention to withdraw from the EU in a move commonly called “Brexit.” It will now have to sever ties from numerous European agencies within the 2-year transition window, including the EMA. Since the drug regulatory body’s inception 22 years ago, it has been located in London, but it will now have to find a new home by March 2019.
According to Reuters, Guido Rasi, the EMA’s executive director, voiced concerns that moving the agency could throw a wrench in its operations, which ensure the safety of the medicines taken by the 743 million residents of the EU. He is particularly worried that the European Council would drag its feet in determining the future home of the agency and its 900 staff. Italy, Denmark, Sweden, Spain, France, Ireland, and Poland have all expressed interest in becoming the EMA’s final destination. The decision could be made as early as this June, and Rasi expressed his view that a quick transition period is essential to getting the agency’s work back on track.
Complicating the issue is the depleted work force of the EMA, as Reuters reports it is having a hard time recruiting replacements for several key staff who have left the agency. It normally receives around 2000 applications for its training program, but this year has only gotten 700.
The EMA already has a significant amount of work on its plate, including in the field of biosimilar review and approval, as it now prepares for the upheaval of moving. In March, for instance, Amgen announced that it had filed for European approval of its trastuzumab biosimilar used to treat breast cancer, joining 3 other trastuzumab biosimilar applications in the agency’s queue. According to the EMA’s website, it was in the process of evaluating 37 proposed biosimilars or non-orphan generics as of February.
A second question associated with the move will be that of redistributing the drug application reviews among 27 other countries, after Britain pulls out. Britain is expected to face the most impact, as the other countries currently contribute 80% of the work. Rasi suggested that EU and British leaders may forge an agreement that allows for mutual recognition of drug approvals in an effort to alleviate the burden to both sides. This deal could include components like the one announced in March between the US and the EU, which indicated that the regulatory bodies will mutually recognize one another’s pharmaceutical manufacturing inspections.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.